|
IVAX sees quarterly net up; generic Taxol sales down THURSDAY, SEPTEMBER 20, 2001 8:14 AM - Reuters MIAMI, Sept 20 (Reuters) - Drug firm IVAX Corp. (AMEX:IVX) said on Thursday it expects third-quarter earnings to be higher, but sales of its generic Taxol cancer drug will drop because of shipping problems resulting from last week`s air attacks on the World Trade Center. "We anticipate IVAX` earnings for the third quarter will be substantially higher than those of last year`s comparable quarter," the company said in a letter to shareholders. "However, as the current quarter is still in progress we cannot be more specific at this time." It said the Sept. 11 attacks had resulted in some back-up delays and disruption in the transportation system bringing raw materials from overseas suppliers and shipping finished goods worldwide. "We are attempting to make alternative arrangements to minimize this situation," the letter said. "Furthermore, with the previous widely reported presence of new competitors in the U.S. generic paclitaxel marketplace, and their subsequent lowering of prices, IVAX` revenues for this product in the third quarter will be significantly lower than in the second quarter." Sales of the generic version of the breast and ovarian cancer drug Taxol, have been driving IVAX earnings recently das vorjahresergebnis war umsatz: 182 mille profit: 30,7 mille per shares 0.15 |
|
| aus der Diskussion: | generics |
| Autor (Datum des Eintrages): | dosto (23.09.01 19:57:58) |
| Beitrag: | 19 von 125 (ID:4483320) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |